Egyszerű nézet

dc.contributor.author Harisi R
dc.contributor.author Jeney, András
dc.date.accessioned 2016-06-27T09:41:59Z
dc.date.available 2016-06-27T09:41:59Z
dc.date.issued 2015
dc.identifier 84934282532
dc.identifier.citation pagination=1387-1398; journalVolume=8; journalTitle=ONCOTARGETS AND THERAPY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/3001
dc.identifier.uri doi:10.2147/OTT.S48883
dc.description.abstract The aim of the present review is to survey the accumulated knowledge on the extracellular matrix (ECM) of tumors referring to its putative utility as therapeutic target. Following the traditional observation on the extensive morphological alteration in the tumor-affected tissue, the well-documented aberrant cellular regulation indicated that ECM components have an active role in tumor progression. However, due to the diverse functions and variable expression of proteoglycans, matrix proteins, and integrins, it is rather difficult to identify a comprehensive therapeutic target among ECM components. At present, the elevated level of heparanase and the prominent expression of αvβ5 integrin are considered as promising therapeutic targets. The inhibition of glycosaminoglycan offers another promising approach in the treatment of those tumors which are stimulated by proteoglycans. It can be ascertained that a selective ECM inhibitor would be a great asset to control metastasis driven by ECM-mediated signaling. © 2015, Harisi and Jeney.
dc.relation.ispartof urn:issn:1178-6930
dc.title Extracellular matrix as target for antitumor therapy
dc.type Journal Article
dc.date.updated 2016-01-04T13:15:57Z
dc.language.rfc3066 en
dc.identifier.mtmt 2990219
dc.contributor.department SE/AOK/I/I. Sz. Patológiai és Kísérleti Rákkutató Intézet
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet